loading...| Preferred Name |
thalidomide |
|
| Synonyms |
2-(2,6-dioxopiperidin-3-yl) isoindoline-1,3-dione [source: IUPAC] |
|
| Definitions |
Anticancer Drug Directed Against Endothelial Growth Factor Receptor <ncicp:ComplexDefinition><ncicp:def-definition>A synthetic derivative of glutamic acid (alpha-phthalimido-glutarimide) with teratogenic, immunomodulatory, anti-inflammatory and anti-angiogenic properties. Thalidomide acts primarily by inhibiting both the production of tumor necrosis factor alpha (TNF-alpha) in stimulated peripheral monocytes and the activities of interleukins and interferons. This agent also inhibits polymorphonuclear chemotaxis and monocyte phagocytosis. In addition, thalidomide inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), thereby inhibiting angiogenesis.</ncicp:def-definition></ncicp:ComplexDefinition> |
|
| ID |
http://purl.bioontology.org/ontology/npo#NPO_434 |
|
| comment |
Anticancer Drug Directed Against Endothelial Growth Factor Receptor |
|
| code |
NPO_434 |
|
| dBXrefID |
NCIT: C870 |
|
| definition |
<ncicp:ComplexDefinition><ncicp:def-definition>A synthetic derivative of glutamic acid (alpha-phthalimido-glutarimide) with teratogenic, immunomodulatory, anti-inflammatory and anti-angiogenic properties. Thalidomide acts primarily by inhibiting both the production of tumor necrosis factor alpha (TNF-alpha) in stimulated peripheral monocytes and the activities of interleukins and interferons. This agent also inhibits polymorphonuclear chemotaxis and monocyte phagocytosis. In addition, thalidomide inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), thereby inhibiting angiogenesis.</ncicp:def-definition></ncicp:ComplexDefinition> |
|
| label |
thalidomide |
|
| preferred_name |
thalidomide |
|
| prefixIRI |
npo:NPO_434 |
|
| synonym |
2-(2,6-dioxopiperidin-3-yl) isoindoline-1,3-dione [source: IUPAC] |
|
| subClassOf |